Novo Nordisk reported DKK37.21B in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Bausch Health Companies USD 2.04B 42M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Eli Lilly USD 10.02B 285M Mar/2026
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Novartis USD 9.29B 507M Mar/2026
Novo Nordisk DKK 37.21B 9.56B Mar/2026
Novo Nordisk DKK 6.5B 32.8B Jun/2025
Pacira USD 172.75M 20.93M Mar/2026
Sanofi EUR 9.31B 1.2B Mar/2026
Supernus Pharmaceuticals USD 1.08B 879.06M Mar/2026